Recurrent Pleural Effusion: Causes, Treatments & Outlook

Recurrent pleural effusion is a buildup of fluid between the membranes lining the lungs and chest wall that returns after being drained, and it signals that the underlying process driving fluid accumulation has not been resolved. The causes span a wide range, from advanced cancers to heart failure to liver disease, and the treatment approach depends heavily on which one is responsible. Because the fluid itself causes breathlessness and chest discomfort, managing recurrence is as much about maintaining quality of life as it is about addressing the root disease.

Why the Fluid Keeps Coming Back

The pleural space normally holds only a thin film of fluid that lubricates the lung surfaces as you breathe. This fluid is continuously produced and reabsorbed, and the balance is maintained by pressure gradients across blood vessels, the permeability of the pleural membranes, and lymphatic drainage that removes excess fluid. A recurrent effusion means one or more of those mechanisms is persistently disrupted. The three broad categories of disruption are changes in the pressure balance that governs fluid movement, impaired lymphatic drainage, and increased permeability of the blood vessels or pleural membranes themselves.¹

Lymphatic blockage is a common culprit in recurrence. When cancer cells, infection, or fibrin deposits physically obstruct the tiny openings (called stomata) in the parietal pleura that funnel fluid into the lymphatic system, the body loses its main route for clearing pleural fluid. Even if you drain the space with a needle, the lymphatic obstruction persists and the fluid returns. Increased blood vessel permeability, which happens when vessel walls develop gaps between cells or new channels through them, tends to underlie most “exudative” effusions, the protein-rich type associated with infection, inflammation, and malignancy.¹

Malignant Causes

Cancer is one of the most common and clinically significant reasons for recurrent pleural effusion. Most malignant pleural effusions arise from cancers that have spread to the pleura from elsewhere in the body rather than from tumors that originate there. Lung cancer in men and breast cancer in women are the leading causes, together accounting for roughly half to two-thirds of all malignant pleural effusions.² Mesothelioma, the primary tumor of the pleural lining itself, produces an effusion in more than 90% of cases.²

The usual pathway for metastatic spread to the pleura is through the bloodstream. Tumor cells from the lung typically travel via pulmonary blood vessels to the visceral pleura (the membrane directly covering the lung). From there, cancer seeds across adhesions or floats freely in the pleural fluid to colonize the parietal pleura on the chest wall side. Once established, the tumor disrupts lymphatic drainage and increases membrane permeability, creating a self-reinforcing cycle: more tumor, more fluid, and more fluid providing a medium for further tumor spread.² This is why malignant effusions so reliably recur after simple drainage and why more definitive interventions are usually necessary.

Non-Malignant Causes

Not every recurrent effusion is caused by cancer. Heart failure and liver cirrhosis are two of the most common benign conditions that produce effusions which keep coming back. Both carry their own sobering prognosis, because recurrent effusion in these settings typically reflects advanced disease. Heart failure effusions develop when elevated venous pressures push more fluid across the pleural membranes than the lymphatic system can absorb. Hepatic hydrothorax, the effusion seen in cirrhosis, results from ascitic fluid tracking through small defects in the diaphragm into the chest.³

In both conditions, the first-line approach is treating the underlying disease with diuretics, sodium restriction, or optimization of cardiac function. When the effusion is refractory to these measures and keeps requiring drainage, more invasive options come into play. For cirrhosis patients who do not respond to diuretics, a procedure called a transjugular intrahepatic portosystemic shunt (TIPS) can relieve the pressure driving fluid production and serve as a bridge to liver transplantation.³ Other benign causes of recurrence include kidney disease (nephrotic syndrome), autoimmune conditions like lupus and rheumatoid arthritis, and infections such as tuberculosis, particularly in parts of the world where TB remains prevalent.

How Doctors Sort Out the Cause

When fluid is drawn from the pleural space, the first diagnostic step is determining whether it is a transudate (low-protein, pressure-driven fluid, as in heart failure) or an exudate (protein-rich fluid caused by inflammation, infection, or malignancy). The standard method for making this distinction, called Light’s criteria, compares the protein and lactate dehydrogenase levels in the fluid against those in the blood. Studies consistently find this approach accurate in the high 90% range for identifying exudates.⁴ Other markers such as pleural fluid cholesterol and D-dimer levels have also shown strong diagnostic accuracy for distinguishing the two types.⁵

When cancer is suspected, the fluid is sent for cytology, which involves looking for malignant cells under a microscope. The detection rate from cytology alone runs around two-thirds of cases. Pleural biopsy catches a slightly lower proportion individually, but combining both methods pushes the yield above 80%.⁶ This matters for recurrent effusions because a firm diagnosis of malignancy changes the treatment plan. If initial cytology is negative but suspicion remains high, a thoracoscopy (inserting a camera into the pleural space) can provide direct biopsy samples and is often performed at the same time as a therapeutic procedure.

Pleurodesis Versus Indwelling Pleural Catheters

Once a recurrent effusion is confirmed, the two main strategies for preventing re-accumulation are pleurodesis and indwelling pleural catheters (IPCs). Pleurodesis involves introducing a substance, most commonly talc, into the pleural space to trigger inflammation that fuses the two pleural membranes together, effectively eliminating the space where fluid collects. An IPC is a thin silicone tube tunneled under the skin into the pleural space that allows fluid to be drained at home on a regular schedule. Both approaches have distinct advantages, and the best choice depends on the patient’s prognosis, the type of effusion, and personal preferences.

The largest head-to-head trials show that both methods improve breathlessness to a similar degree. In the TIME2 trial, patients randomized to IPCs and those randomized to chest-tube talc pleurodesis reported nearly identical improvements in dyspnea scores over six weeks.⁷ The AMPLE-2 trial found that patients with IPCs spent fewer total days in the hospital, with the reduction driven mainly by fewer effusion-related hospitalization days. Fewer patients in the IPC group needed further invasive drainage procedures on the same side compared with those who underwent pleurodesis (about 4% versus roughly 23%).⁸

For pleurodesis specifically, how the talc is delivered matters. Talc poudrage (insufflated as a dry powder during thoracoscopy) tends to outperform talc slurry (mixed with saline and instilled through a chest tube). One prospective comparison found lifelong success rates of about 82% for poudrage versus 62% for slurry.⁹ A large intergroup trial, however, found less dramatic differences at 30 days and flagged higher rates of respiratory complications with poudrage.¹⁰ The evidence is strong enough that lung and breast cancer patients seem to benefit more from poudrage, but the procedure requires thoracoscopy and anesthesia, which not every patient can tolerate.

Combining Approaches

Clinicians have increasingly explored hybrid strategies that pair an IPC with talc instillation to get the best of both worlds: outpatient convenience and a higher chance of achieving pleurodesis so the catheter can eventually be removed. The IPC-PLUS trial randomized patients with malignant effusions to receive either talc slurry or placebo through their IPC. At five weeks, about 43% of those receiving talc had achieved pleurodesis compared with 23% in the placebo group.¹¹ A smaller French series combining talc poudrage at the time of IPC insertion reported pleurodesis rates of about two-thirds at one month, climbing to roughly 85% by three months.¹²

When an IPC is used on its own, spontaneous pleurodesis (the pleural surfaces sticking together without any chemical agent) still occurs in a meaningful proportion of patients. One prospective study reported it in about a third of all IPC patients, though the rate was lower in malignant effusions (about 28%) compared with non-malignant effusions (50%).¹³ When pleurodesis does happen, the catheter can be removed and the patient is free of ongoing drainage. Another approach used a wall-suction pump device to create continuous negative pressure through the catheter, which accelerated pleurodesis in over three-quarters of patients within a mean of about 19 days.¹⁴

IPC Complications and How They’re Managed

Living with an indwelling catheter carries some risks. Symptom relief is reported in about 85% of patients, and recurrence after successful IPC management is rare (around 3% in one study).¹³ But catheter blockage, chest pain, fluid loculation (pocketing of fluid that the catheter can’t reach), and pleural infection each occur at rates between roughly 9% and 16%.¹³

Infection is the complication that worries patients most. It occurs in roughly 5–6% of IPC cases and typically shows up at least six to eight weeks after insertion, suggesting it’s not related to the procedure itself but rather to bacteria migrating along the catheter tract over time.¹⁵ ¹⁶ Skin bacteria, especially Staphylococcus species, are responsible for most cases. This is why careful aftercare and good drainage technique at home matter more than prophylactic antibiotics at the time of insertion.¹⁶

The reassuring part is that mortality from IPC-related pleural infection is very low, below 0.5% of all IPC-treated patients in one large series. Most infections resolve with antibiotics, more than a quarter of them managed entirely as outpatients with oral medications. The catheter itself rarely needs to be removed.¹⁶ An interesting twist is that a deep pleural infection around an IPC often triggers pleurodesis as a side effect of the inflammation, which can be a silver lining in a difficult situation.¹⁵

Non-Malignant Recurrent Effusions and Treatment Options

When the effusion is driven by heart failure, cirrhosis, kidney disease, or autoimmune conditions, the first priority is optimizing treatment of that underlying disease. Diuretics, fluid restriction, and disease-specific medications resolve many effusions without any procedure on the chest itself. However, a subset of patients remain “refractory,” meaning the fluid returns despite aggressive medical management.¹⁷

For these patients, the procedural options mirror those used in malignant effusions: repeated therapeutic taps, talc pleurodesis, or IPC placement.¹⁷ IPCs have shown particular promise in benign recurrent effusions, reducing hospitalizations and improving respiratory symptoms even in patients whose underlying disease cannot be cured.¹⁸ The spontaneous pleurodesis rate with IPCs appears higher in non-malignant effusions (around 50%) than in malignant ones, which means there’s a better chance the catheter can be removed in this group.¹³

Predicting Outcomes in Malignant Effusions

One of the hardest conversations around malignant pleural effusion involves prognosis. The presence of a malignant effusion generally indicates advanced disease, but survival varies enormously depending on the cancer type, overall fitness, and how the body is responding to the tumor. The LENT scoring system was developed to bring some structure to this uncertainty. It combines four readily available data points: pleural fluid LDH level, a standard performance score, the serum neutrophil-to-lymphocyte ratio, and the tumor type. Patients are sorted into low, moderate, and high-risk categories.¹⁹

The LENT score has been validated in multiple populations and consistently outperforms simpler measures of patient fitness at predicting survival at one, three, and six months.¹⁹ ²⁰ This matters practically because prognosis shapes treatment decisions. A patient classified as high risk with expected survival measured in weeks would rarely benefit from a talc pleurodesis requiring a hospital stay and chest tube; an IPC placed in an outpatient setting and drained at home makes much more sense. Conversely, a low-risk patient with months or years ahead may prefer the more definitive closure of pleurodesis so they don’t have to live with an external catheter. Cost-effectiveness analyses support this logic: IPCs tend to be the more economical choice when expected survival is short (under roughly 14 weeks), while pleurodesis becomes more cost-effective for patients who live longer, partly because ongoing nursing time for catheter drainage adds up.²¹

Quality of Life After Intervention

The primary goal of treating a recurrent effusion is almost always symptom relief rather than cure, so quality-of-life outcomes matter at least as much as procedure success rates. Across studies, draining pleural fluid reliably improves breathlessness, and this improvement shows up consistently on simple one-dimensional measures like visual analog scales for dyspnea.²² More complex quality-of-life questionnaires that try to capture physical function, emotional well-being, and activity levels show less consistent improvement, likely because many of these patients have advanced disease affecting their lives in ways that fluid drainage cannot fix.²²

A Brazilian study of IPC patients with malignant effusions illustrates this tension. Breathlessness improved significantly after catheter placement and stayed improved, but broader quality-of-life scores, including pain, functional capacity, and global health status, did not change in a statistically meaningful way.²³ The takeaway for patients is realistic expectations: you will breathe better, and that alone can be transformative, but the catheter will not reverse the impact of advanced cancer or severe organ failure on your overall energy and daily function.

Recurrent Effusions in Children

Pleural effusions in children are uncommon, and recurrence is rarer still, but when it happens the causes differ markedly from adults. Cancer is a much less frequent driver. Instead, chylothorax, a leakage of lymphatic fluid rich in fats, is a leading cause of persistent or recurrent effusion in pediatric patients. In one series of 51 children with chylothorax, about 65% of cases were caused by direct injury to the thoracic duct during cardiothoracic surgery, while about 27% resulted from high venous pressures or blood clots in the superior vena cava. A small group (about 8%) had congenital lymphatic abnormalities.²⁴

Conservative treatment, primarily dietary changes that reduce lymphatic flow (such as medium-chain triglyceride diets or fasting with intravenous nutrition), resolved the effusion in 80% of those children. However, patients whose chylothorax was caused by high venous pressures or congenital abnormalities were significantly more likely to need surgical intervention.²⁴ The general lesson from pediatric cases is that the underlying mechanism matters enormously: direct duct injury is a mechanical problem that usually heals, while systemic lymphatic or venous disorders are harder to control.

Emerging Treatments

For malignant effusions specifically, the research horizon is moving beyond mechanical solutions (drain it or seal it) toward therapies that target the biology driving the fluid. The pleural space in cancer patients is not just a passive reservoir; it is an immunologically suppressed environment where the tumor actively disables the immune cells that should be fighting it. Emerging approaches use nanotechnology, gene editing tools, and engineered biomaterials to deliver immune-activating agents directly into this microenvironment. Examples in early-stage research include nanoparticles loaded with cytokines (immune signaling proteins) and oncolytic viruses designed to infect and destroy tumor cells while stimulating an immune response.²⁵

These technologies are still largely preclinical or in early trials, so they are years from routine clinical use. But the concept represents a genuine shift in thinking: rather than accepting that malignant effusions are a side effect to be managed with plumbing, the field is exploring whether the effusion itself can be turned into a treatment arena where the immune system is re-engaged against the tumor. For patients with recurrent malignant effusions today, the practical landscape remains pleurodesis, IPCs, or a combination, but the pipeline suggests that future options may address the disease process more directly rather than just the symptom of fluid accumulation.

1
European Respiratory Journal. Physiology and pathophysiology of pleural fluid turnover
2
European Respiratory Review. Malignant pleural effusion: from bench to bedside
3
PubMed. Expert Review on Contemporary Management of Common Benign Pleural Effusions
4
PubMed Central. Comparison of the Efficacy of Light’s Criteria With Serum-Effusion Albumin Gradient and Pleural Effusion Glucose
5
NATIONAL JOURNAL OF LABORATORY MEDICINE. Diagnostic Accuracy of Light’s Criteria, Alkaline Phosphatase, Total Cholesterol, and D-dimer in Differentiating Transudative and Exudative Pleural Effusion: A Cross-sectional Study
6
Int Jr Cardiac Sci and Res. Cytology versus Biopsy Yield in Patients with Malignant Pleural Effusion at the Lagos University Teaching Hospital, Nigeria: A prospective review
7
JAMA. Effect of an Indwelling Pleural Catheter vs Chest Tube and Talc Pleurodesis for Relieving Dyspnea in Patients With Malignant Pleural Effusion: The TIME2 Randomized Controlled Trial
8
PubMed Central. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion
9
PubMed. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion: A prospective comparative study
10
Chest. Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion
11
PubMed. Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion
12
PubMed. Fast pleurodesis combining talc poudrage and indwelling pleural catheter for the management of recurrent malignant pleural effusions
13
PubMed Central. Indwelling pleural catheter efficacy and safety in malignant vs. non-malignant pleural effusions: a prospective study
14
PubMed. Safety and efficacy of using a surgivac pump for the drainage of chronic indwelling pleural catheters in malignant pleural effusions
15
PubMed Central. Indwelling pleural catheter infection and colonisation: a clinical practice review
16
BMJ. Complications of indwelling pleural catheter use and their management
17
European Respiratory Review. The management of benign non-infective pleural effusions
18
PubMed. The use of a PleurX catheter in the management of recurrent benign pleural effusion: a concise review
19
PubMed Central. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score
20
PubMed Central. Validating LENT score in malignant pleural effusion
21
PubMed. Cost-effectiveness of indwelling pleural catheter compared with talc in malignant pleural effusion
22
PubMed Central. Patient-Reported Outcomes in Pleural Effusions: A Systematic Review
23
Clinics. Quality of life in patients with malignant pleural effusion treated with an indwelling pleural catheter in an emerging country
24
PubMed Central. Etiology and management of pediatric chylothorax
25
Critical Reviews in Oncology/Hematology. Novel bioengineered drugs with immunotherapies for malignant pleural effusion: Remodulate tumor immune microenvironment and activate immune system